Eli Lilly and Company and Eli Lilly Canada Inc. have filed a motion requesting among other things certiorari to quash the issuance of a notice of compliance (NOC) to Apotex Inc. on April 30 1997 in respect of the drug nizatidine. The issue in the proceeding is whether the synthetic process disclosed to the applicants by Apotex Inc. is the same process set out in the New Drug Submission (NDS). Eli Lilly and Company are requesting that they be allowed to file reply evidence within a period of seven days of the order allowing the present application and the respondent is granted the right to cross-examine on the reply affidavits.